Articles tagged with Cancer Treatments
Researchers found GZ17-6.02 alone and in combination with standard-of-care agents was effective in killing MF cells, activating key pathways including ATM, AMPK, NFκB, and macroautophagy. The compound's unique multi-factorial mechanism suggests potential for treating mycosis fungoides.
A recent study by Cold Spring Harbor Laboratory researchers reveals that chronic stress can increase cancer's ability to spread. By mimicking chronic stress in mice with cancer, the team discovered that stress causes neutrophils to form sticky web-like structures called NETs, making body tissues more susceptible to metastasis.
Researchers developed a CRISPR RNA-editing platform to regulate immune cell metabolism, boosting anti-tumor function and sustaining T cell proliferation. The platform enables reversible changes to gene expression and can be controlled by a drug, offering a safety switch for immunotherapy treatments.
Researchers identified a putative paclitaxel response predictive biomarker for glioblastoma and breast cancer using the whole genome CRISPR knockout screen. The biomarker candidate was validated in two independent breast cancer patient cohorts that received taxane treatment.
A team of researchers from the University of Tokyo demonstrated that a drug, valemetostat, reduces tumor growth in blood cancer by targeting H3K27me3, a protein modification silencing tumor suppressor genes. The treatment restores expression of many tumor suppressor genes and sustains inhibiting tumor cell growth.
Researchers developed a novel machine learning-based approach to analyze diffuse reflectance spectroscopy data, achieving higher accuracies and speeds than existing methods. The 'wavelength-independent regressor' model overcomes use-error limitations by incorporating diverse datasets, making it suitable for clinical settings.
Recent US nationwide data reveal rising HCC incidence and mortality rates primarily affecting men and older adults. The study highlights disparities among racial/ethnic groups and underscores the need for targeted early detection, intervention, and treatment strategies to improve patient outcomes.
Researchers found that Inuit residents in Nunavik had shorter survival rates for lung cancer compared to Montreal residents, despite similar disease stages. The study attributes this disparity to chronic under-resourcing of healthcare services and lack of Inuit representation in healthcare provision.
Researchers identified NTRK gene fusion in 1.5% of Finnish papillary thyroid cancer patients, with notable co-occurring genetic alterations and favorable treatment outcomes. The study highlights the potential for biobank samples linked to electronic health records to describe patient characteristics and outcomes.
A team of scientists has developed a new treatment for chronic wounds that uses ionized gas plasma to decontaminate and heal wounds. The technology shows promise in treating diabetic foot ulcers, internal wounds, and potentially cancerous tumours.
A study published in Oncotarget has identified specific mutational and therapeutic landscapes of pancreatic cancer in the Russian population. By applying machine learning models to full exome individual data, researchers received personalized recommendations for targeted treatment options for each clinical case.
Researchers discovered that blocking efferocytosis pathway prevents immunosuppressive activity in macrophages, restoring T cell activation and reducing metastatic tumour burden. The study found PDAC metastases to show high levels of immunosuppressive macrophages, promoting tumour growth.
Researchers have developed a new approach to treating cutaneous neurofibromas, a common skin tumor associated with neurofibromatosis type 1. By targeting the cAMP and Ras/MAPK pathways, this combination therapy may provide an enduring halt in the expansion of these tumors.
Researchers developed a novel assay that integrates data from four fusion callers to identify disease-related gene fusions in pediatric tumors with high accuracy and efficiency. The new bioinformatics platform detected fusions, prioritized them, and custom curated downstream processes for consensus fusion calling.
A team of physicists and veterinary scientists at Purdue University has developed a method to detect chemoresistance in cancer patients using biodynamic imaging (BDI). This technique measures the motions inside cancer cells and how they respond to chemotherapy, identifying patients who will not respond to treatment. The study shows pro...
Researchers at Aston University have discovered that aging skin exhibits distinct optical properties under polarised laser light. This finding could lead to the development of non-invasive light-based techniques for early detection and monitoring of skin conditions, including cancer.
A new tumor spatial mapping tool will help clinicians assess the aggressiveness of cancer and personalize treatment. The tool maps the functional state of oncoproteins onto tumour images, allowing for more accurate diagnosis and informed treatment decisions.
Researchers develop a novel genomic classification system that categorizes patients into 12 distinct groups based on their underlying genomic profiles. The individualized risk model, IRMMa, uses advanced statistical methodologies to generate tailored predictions of patient response to different therapies.
Researchers at Weill Cornell Medicine have developed a mouse model that illuminates the process of histological transformation, where adenocarcinoma transforms into aggressive small cell lung cancer. The study suggests targeting Myc proteins as potential therapeutic approaches for this deadly type of cancer.
Researchers found elevated PROX1 levels in advanced colon adenocarcinoma, correlating with poor prognosis. PROX1 modulates CRC cell behavior, influencing invasiveness and survival outcomes. The combined PROX1/α-SMA gene set emerges as a potential CRC prognostic marker.
A microfluidic chip can remove undifferentiated cells that could form tumors before they are implanted in a patient, improving the safety and effectiveness of cell therapy. The device can sort over 3 million cells per minute without causing damage to fully-formed progenitor cells.
A Phase I first-in-human clinical trial has demonstrated the safety and anti-tumor activity of OMO-103, a novel MYC inhibitor. The study showed favorable safety profile with only mild side effects, and notable clinical benefits in patients, including disease stabilization and tumor shrinkage.
A systematic analysis by MedUni Vienna's Center for Public Health found that people experiencing homelessness are twice as likely to develop cancer due to increased exposure to risk factors. Key barriers include lack of access to preventive services, inadequate support from healthcare systems, and traumatic experiences.
Researchers have developed a novel virtual reality-based relaxation therapy that helps cancer patients in palliative care manage symptoms and stress better. The therapy, known as FLOW-VRT-Relaxation, combines standard-of-care relaxation techniques with immersive VR experiences to promote psychological states of flourishing.
Researchers have uncovered the molecular and ultrastructural features of BCAS1+ cells in diffuse gliomas, highlighting their proliferative capacity and distribution. The study provides a comprehensive characterization of the BCAS1+ cell population within diffuse gliomas, shedding light on its role in tumor malignancy.
Researchers have identified regional biological signatures in invasive brain tumor margins of high-grade glioma, which could lead to improved diagnosis, prognosis, and treatment. Advanced MRI techniques may help distinguish between the genetic and molecular alterations, providing insights into resistance to treatment.
A recent study has identified a promising solution to combat resistance to protein degraders, which are a novel approach in drug discovery. The researchers found that the drug RBS-10 selectively removes resistant cells by targeting the enzyme NQO1, which is overexpressed in these cells.
A pilot study proposes a promising global genomic assay for diagnosing molecular subtypes in pediatric B-ALL, leading to more accurate diagnosis and targeted treatment options. RNA sequencing analysis accurately identified subtypes in all known cases and determined genetic subtype in 79% of previously unknown cases.
Researchers report a case of a patient with EGFR L858R mutant non-small cell lung cancer (NSCLC) who experienced durable disease improvement after empirical treatment with osimertinib. The 'Lazarus effect' refers to the phenomenon where cancer appears to recur after seeming to be in remission.
Researchers developed an mRNA therapeutic that combats ovarian cancer by producing functional p53 protein, shrinking and killing tumors. The treatment is effective against metastases and has shown promise in preclinical studies.
Researchers develop technology that alleviates retinal pathologies by targeting mitochondrial chaperone TRAP1, which is implicated in the breakdown of blood-retinal barrier and pathological neovascularization. This treatment approach holds great promise for revolutionizing the treatment landscape for ischemic retinopathy.
High levels of copper linked to poorer patient outcomes in clear cell renal cell carcinoma (ccRCC) patients, according to NIH-funded University of Cincinnati Cancer Center research. The study aims to identify copper's mechanisms and test potential new treatments for ccRCC.
Breast cancer cells survive by consuming the extracellular matrix when nutrients are scarce. The process involves macropinocytosis and metabolic conversion of key amino acids to energy-releasing substrates. This mechanism could represent a novel therapeutic target.
Researchers developed a new imaging technique to visualize the tumor microenvironment of glioblastoma, revealing insights into its pathology. The technique uses PET imaging with Carbon-11 acetate, tracking reactive astrocytes and distinguishing them from tumor cells.
Researchers discuss reductive carboxylation of glutamine as a potential target in acute myeloid leukemia (AML), an aggressive cancer with poor patient outcomes. The approach aims to weaken tumor cell survival mechanisms, potentially leading to novel therapies and improved patient outcomes.
A study by the University of Sheffield found that breast cancer cells take advantage of nutrients in the extracellular matrix when faced with nutrient starvation. The cells use an ingestion process called macropinocytosis to consume the matrix, breaking it down into energy-releasing substrates.
A new method has been developed to detect potential therapeutic tumor targets in human biopsies, which could lead to more effective personalized medicine. The kinase inhibitor pulldown assay (KiP) enriches and quantifies small amounts of kinases present in biopsy samples, paving the way for future clinical applications.
Researchers successfully reduced bladder tumor size by 90% in mice using nanorobots propelled by urea. The nanomachines deliver a radioisotope to the tumour, attacking it with precision and efficiency. This breakthrough could lead to more effective bladder cancer treatments and reduced hospitalization costs.
Researchers from MD Anderson Cancer Center reported a case of a patient with an exceptional response to pazopanib treatment for over 5 years. The study shows that pazopanib prevents or delays the progression of additional metastasis in EWSR1-NFATC2 positive sarcomas. Further studies are warranted.
A systematic analysis of cancer cells identifies 370 candidate priority drug targets across 27 cancer types. Researchers used machine learning methods to find promising targets and linked them to specific biological markers and genetic features.
A team of scientists has identified a previously unrecognized control point in DNA repair processes, which could lead to novel cancer therapies by inhibiting the repair of damaged cancer cells. The newly discovered GSE1-CoREST complex contains three enzymes that control DNA repair and may form the basis for improved cancer treatments.
Researchers developed a blood test, NEMO, to detect neuroendocrine prostate cancer (NEPC) and differentiate it from CRPC-adenocarcinoma. The test uses cell-free DNA methylation changes to quantify tumor burden and identify subtypes.
Researchers analyzed genome sequences from over 4,000 tumours to identify patterns of DNA mutations that vary between individuals. They found 13 distinct patterns, with 10 corresponding to different types of tissue, and discovered that the density of mutations in specific genes varies significantly between individuals.
A landmark national study has shown that combining health data with whole genome sequence (WGS) data can help doctors provide more tailored care for patients with cancer. The research found specific genetic changes associated with better or worse survival rates and improved patient outcomes across different cancer types.
Graphene quantum dots have been designed to enhance catalytic performance using a diatomic doping strategy, resulting in impressive peroxidase-mimicking activity. This metal-free nanozyme has shown high efficacy in inducing apoptosis and ferroptosis of cancer cells with minimal side effects.
Researchers discuss clonal hematopoiesis, a condition where cells harbor somatic mutations, and its association with aging, solid tumors, and treatment outcomes. Emerging evidence suggests that CH may play a role in cancer development and survival.
Researchers summarize the latest progress in comprehending epigenetic pathways and their dysregulation in cancer development. They discuss the therapeutic potential of epigenetic drugs and combination therapies.
Researchers have found a way to control MYC's hyperactivity using a peptide compound with sub-micro-molar affinity. This breakthrough offers hope for more effective treatments for cancer patients.
A ground-breaking study published in Nature Communications sheds light on the intricate mechanisms underlying the virulence of Aspergillus fumigatus, specifically focusing on the crucial role of mycotoxin gliotoxin production. The research team identified pivotal roles played by GliT oxidoreductase and GtmA methyltransferase in the sel...
Cancer stem cell-derived exosomes (CSC-Exos) are essential for communication between CSCs and other cells in the tumor microenvironment, contributing to cancer progression. The editorial highlights their potential as a novel clinical tool for diagnosis, prognosis, prevention of tumor recurrence, and therapeutic strategy
A new framework has been established for standardized imaging of diffuse gliomas using amino acid PET, enabling the evaluation of treatment success and improving therapies. The RANO group has developed criteria that enable reliable imaging of tumor activity and extent.
Researchers have developed nanodrones that target and eliminate cancer cells by recruiting natural killer cells to tumor sites. The study offers a potential solution for intractable types of cancers, with promising results in suppressing tumor growth without causing side effects.
GFH009 inhibits tumor growth and induces apoptosis in various HHM-derived cell lines. The compound's mechanism of action involves rapid 'on-off' inhibition of CDK9, which exerts a proapoptotic effect on cancer cells.
Researchers at UCLA Health have received a $3 million grant to identify novel biomarkers and develop AI for detecting aggressive prostate cancer. The project aims to improve treatment accuracy and reduce unnecessary interventions.
A team of researchers has identified the allosteric control sites found in the protein KRAS, providing a comprehensive map for controlling its effects. The study offers promising targets for safer and more effective drugs, with potential implications for cancer treatment.
Researchers explore the properties of cytostatic persisters in cancer treatment, highlighting their therapeutic potential and challenges. The study suggests that targeting these persisters before resistance emerges can reduce cancer recurrence.
Researchers at TTUHSC are studying a new approach to inhibit STAT3, a protein associated with 70% of human tumors. Disrupting STAT3 synthesis on ribosomes could lead to new cancer treatments.
A Phase III trial demonstrates significantly improved progression-free survival and remission rates for patients with relapsed/refractory mantle cell lymphoma treated with the oral combination of ibrutinib and venetoclax. The treatment achieved an overall remission rate of 82% and a median PFS of 31.9 months.
A phase 1 clinical trial demonstrates the efficacy of third-generation anti-CD19 CAR T-cells in treating relapsed or refractory B-cell non-Hodgkin lymphomas without causing neurotoxicity. The study also shows a robust response rate of 52% and improved safety profile compared to previous CAR T-cell therapies.
Researchers discuss recent advances in blood-based liquid biopsies for prostate cancer interrogation, highlighting key biomarkers like CTCs, ctDNA, and exosomes. The studies suggest that these approaches can aid in predicting tumor recurrence, improving treatment response, and evaluating prognosis.